NCT02801201

Brief Summary

At the time of birth, nearly 5% of children are in breech presentation. This type of presentation requires a medical environment and leads to more frequent use of Caesarean sections. This is why the external version can be proposed, usually from the 36th week. Its success rate is 40%, and is usually performed under simple sedation. One of the causes of failure is the lack of relaxation of the uterus, which could be higher in case of deeper anesthesia, as is the case in spinal anesthesia. The study project is to demonstrate superiority of spinal anesthesia compared to the usual protocol sedation in terms of primary and secondary objectives.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started May 2016

Typical duration for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 27, 2016

Completed
4 days until next milestone

Study Start

First participant enrolled

May 31, 2016

Completed
15 days until next milestone

First Posted

Study publicly available on registry

June 15, 2016

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 30, 2019

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2019

Completed
Last Updated

August 8, 2018

Status Verified

August 1, 2018

Enrollment Period

3.4 years

First QC Date

May 27, 2016

Last Update Submit

August 7, 2018

Conditions

Keywords

sedationspinal anesthesia

Outcome Measures

Primary Outcomes (1)

  • Successful external version (VME) upon completion gesture : obtaining a fetus in cephalic presentation

    24 hours

Secondary Outcomes (5)

  • occurrence of side events due to the manipulation itself

    Day 0

  • occurrence of side events due to anesthesia

    Day 0

  • The pain experienced by the patient: assessed by the Visual Analogic Scale

    Day 0

  • The final delivery mode (caesarian section or vaginal)

    Day 0

  • The presentation in childbirth

    Day 0

Study Arms (2)

sedation

ACTIVE COMPARATOR

Midazolam : 0,10 mg/kg

Drug: Midazolam

spinal anesthesia

ACTIVE COMPARATOR

Bupivacain 10 mg

Drug: Bupivacaine

Interventions

sedation
spinal anesthesia

Eligibility Criteria

Age18 Years - 60 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • age ≥ 18 years
  • patient with 36 weeks of amenorrhea (SA) a fetus breech or transverse presentation
  • covered by a an insurance system
  • signed contentment

You may not qualify if:

  • Obstetric contraindications:
  • placenta previa
  • rd trimester bleeding
  • suspicion of fetal anoxia
  • patient has already received more than one caesarean section
  • multi-fetal pregnancy
  • HIV +
  • anticoagulant therapy
  • Anesthesiologic contraindications:
  • infection at the puncture site, systemic infection or severe sepsis
  • intracranial hypertension
  • uncompensated heart failure
  • constitute or acquired coagulation abnormalities, including anticoagulant therapy with curative intent
  • neuropathy with demyelination of nerve fibers in thrust or unstabilized during recovery
  • syringomyelia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Amiens

Amiens, 80054, France

RECRUITING

MeSH Terms

Conditions

Breech Presentation

Interventions

MidazolamBupivacaine

Condition Hierarchy (Ancestors)

Obstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Intervention Hierarchy (Ancestors)

BenzodiazepinesBenzazepinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Officials

  • Julien CHEVREAU, MD

    CHU Amiens

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 27, 2016

First Posted

June 15, 2016

Study Start

May 31, 2016

Primary Completion

October 30, 2019

Study Completion

November 30, 2019

Last Updated

August 8, 2018

Record last verified: 2018-08

Locations